We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DRRX
2801
DELISTED
DURECT Corp
DRRX
$150K ﹤0.01%
15,192
-3,976
-21% -$43.9K
LHDX
2802
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$150K ﹤0.01%
17,400
+7,200
+71% +$45.8K
SHCR
2803
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
$149K ﹤0.01%
+33,200
New +$214K
ALDX icon
2804
Aldeyra Therapeutics
ALDX
$86.9M
$148K ﹤0.01%
37,064
+25,900
+232% +$198K
EGY icon
2805
Vaalco Energy
EGY
$592M
$148K ﹤0.01%
46,000
SPWH icon
2806
Sportsman's Warehouse
SPWH
$46.8M
$145K ﹤0.01%
12,293
-3,500
-22% -$54.9K
RIGL icon
2807
Rigel Pharmaceuticals
RIGL
$762M
$144K ﹤0.01%
5,446
-350
-6% -$10.6K
ENZ
2808
DELISTED
Enzo Biochem, Inc.
ENZ
$144K ﹤0.01%
44,800
LCTX icon
2809
Lineage Cell Therapeutics
LCTX
$268M
$143K ﹤0.01%
58,391
-57,300
-50% -$134K
EPZM
2810
DELISTED
Epizyme, Inc
EPZM
$143K ﹤0.01%
57,258
-36,900
-39% -$145K
IZEA icon
2811
IZEA Worldwide
IZEA
$53.8M
$140K ﹤0.01%
26,125
+6,375
+32% +$46.1K
OIS icon
2812
Oil States International
OIS
$526M
$140K ﹤0.01%
28,162
-1,052
-4% -$6.19K
MBT
2813
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
$140K ﹤0.01%
17,600
ME
2814
DELISTED
23andMe Holding Co
ME
$137K ﹤0.01%
+1,030
New +$190K
SUNW
2815
DELISTED
Sunworks, Inc.
SUNW
$137K ﹤0.01%
44,600
+15,600
+54% +$79.9K
TAST
2816
DELISTED
Carrols Restaurant Group, Inc.
TAST
$136K ﹤0.01%
45,941
+7,500
+20% +$25.1K
LUNA
2817
DELISTED
Luna Innovations Incorporated
LUNA
$135K ﹤0.01%
+16,015
New +$144K
GNE icon
2818
Genie Energy
GNE
$386M
$133K ﹤0.01%
23,842
NAGE
2819
Niagen Bioscience
NAGE
$241M
$133K ﹤0.01%
35,672
-1,000
-3% -$5.4K
OMIC
2820
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$133K ﹤0.01%
+383
New +$148K
KPTI icon
2821
Karyopharm Therapeutics
KPTI
$45.1M
$131K ﹤0.01%
1,361
-1,633
-55% -$163K
MDXG icon
2822
MiMedx Group
MDXG
$612M
$131K ﹤0.01%
21,753
-30,898
-59% -$215K
SEAC
2823
DELISTED
Seachange International Inc
SEAC
$131K ﹤0.01%
4,095
AMWL icon
2824
American Well
AMWL
$220M
$130K ﹤0.01%
1,077
-1,249
-54% -$190K
HROW icon
2825
Harrow
HROW
$1.46B
$130K ﹤0.01%
15,100
+4,400
+41% +$43.5K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.